AI assistant
Bionano Genomics, Inc. — Director's Dealing 2020
Apr 7, 2020
35041_dirs_2020-04-07_2609d3d2-c8b0-44d7-ae26-aea6cceb216f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Bionano Genomics, Inc (BNGO)
CIK: 0001411690
Period of Report: 2020-04-06
Reporting Person: TWOMEY CHRISTOPHER J (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-04-06 | Common Stock | A | 45000 | $0.32 | Acquired | 64500 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-04-06 | Common Stock Warrants (right to buy) | $0.33 | A | 45000 | Acquired | 2025-04-06 | Common Stock (45000) | Indirect |
Footnotes
F1: Acquired from the Issuer pursuant to an Underwriting Agreement dated April 1, 2020 with a closing date of April 6, 2020. The Underwriting Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors.
F2: The total per share and accompanying common warrant price offered in the public offering is $0.33. Each share of common stock is being sold together with a common warrant to purchase one share of the Company's common stock. The public offering price, per share is $0.32 and per common warrant is $0.01.